Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Methodological detailsliterature review of the Medline database from years 2011 to May 2024
- Literature review of the Medline database from years 2011 to May 2024
Recommendations
As issued by the authors
Re-affirm serum/plasma tPINP and plasma β-CTX-I as reference bone turnover markers (BTMs), with appropriate patient preparation, sample handling and standardized/harmonized assays, in clinical studies to accumulate further data, and for monitoring osteoporosis treatment with normal renal function in clinical practice
Bone alkaline phosphatase (BALP) and TRACP5b, measured by standardized assays, recommended as reference BTMs for CKD-associated osteoporosis; to be included in observational and intervention studies to ascertain utility for risk-evaluation, treatment initiation and assessment of treatment response
Treatment-induced changes in PINP and β-CTX-I recommended for inclusion in studies to examine adherence in individual patients
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →